Table 1.

Main general features and long-term follow-up of a series of 103 patients with refractory uveitis due to Behçet disease (BD) treated with IFX.

Values
No. patients/eyes affected103/185
Age, yrs, mean (SD)40.4 (10.1)
Sex, male/female, n (%)55/48 (53.4/46.6)
HLA-B51–positive, %69.4
Duration of BD before IFX, months, median (IQR)40 (17–87)
Duration of uveitis before IFX, months, median (IQR)36 (12–72)
Ocular features at the time of IFX onset
    AC cell count, median (IQR)1 (0–2)
    Vitritis, median (IQR)1 (0–2)
    BCVA, mean (SD)0.44 (0.28)
    OCT, mean (SD)337.7 (121.8)
    Retinal vasculitis, % affected eyes58
Pattern of uveitis, n (%)
    Bilateral/unilateral82/21 (79.6/20.4)
    Anterior11 (10.7)
    Posterior28 (27.2)
    Panuveitis64 (62.1)
Previous treatment to anti-TNF onset, n (%)
    CSA77 (74.8)
    AZA58 (56.3)
    MTX45 (43.7)
    Pulses of IV MP30 (29.1)
    Oral glucocorticoids100 (100)
    Other treatments34 (33.0)
Prednisone dose at IFX onset, mg/d, median (IQR)30 (20–45)
Regimen of IFX therapy
    Monotherapy/combined treatment, n (%)25/78 (24.2/75.8)
        AZA17 (16.5)
        CSA32 (31.1)
        MTX26 (25.2)
        MMF1 (1)
        Tacrolimus1 (1)
        CYC1 (1)
    IFX dosage, n (%)
        3 mg/kg IV, 0, 2, 6 wks, then every 4–8 weeks8 (7.8)
        4 mg/kg IV, 0, 2, 6 wks, then every 4–8 weeks1 (1)
        5 mg/kg IV, 0, 2, 6 wks, then every 4–8 weeks94 (91.2)
        Follow-up on IFX therapy, mos, mean (SD)31.5 (23.5)
    Remission, n (%)78 (76.5)
    Discontinuation treatment, n (%)57 (55.3)
Remission20 (19.4)
Inefficacy18 (17.5)
Side effects/toxicity9 (8.7)
Other10 (9.7)
Severe side effects, per 100 patients/yr, n (%)9 (8.7)

  • AC: anterior chamber; ADA: adalimumab; AZA: azathioprine; BCVA: best-corrected visual acuity; CYC: cyclophosphamide; CSA: cyclosporine A; IFX: infliximab; IV: intravenous; MMF: mycophenolate mofetil; MTX: methotrexate; MP: methylprednisolone; OCT: optical coherence tomography; TNF: tumor necrosis factor-α.